Abstract Anti-PD-1/PD-L1 monoclonal antibodies have substantially improved the overall
survival of a subset of patients across multiple solid tumour types, but other patients can …

Since the mid-1990s, dendritic cells have been used in clinical trials as cellular mediators for
therapeutic vaccination of patients with cancer. Dendritic cell-based immunotherapy is safe …

Purpose GVAX pancreas, granulocyte-macrophage colony-stimulating factor–secreting
allogeneic pancreatic tumor cells, induces T-cell immunity to cancer antigens, including …

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic
Castration-Resistant Prostate Cancer - PMC Back to Top Skip to main content NIH NLM …

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim
to treat late stage disease by using a patient's own immune system. The promising results …

The anecdotal reports of promising results seen with immunotherapy and radiation in
advanced malignancies have prompted several trials combining immunotherapy and …

BACKGROUND Chimeric antigen receptor (CAR)‐modified “designer” T cells (dTc, CAR‐T)
against PSMA selectively target antigen‐expressing cells in vitro and eliminate tumors in …

In the last few years, immunotherapy has become an important cancer treatment modality,
and although the principles of immunotherapy have evolved over many decades, the FDA …

Increasing knowledge of intertumor heterogeneity, intratumor heterogeneity, and cancer
evolution has improved the understanding of anticancer treatment resistance. A better …

Immunotherapy is an important breakthrough in cancer. US Food and Drug Administration-
approved immunotherapies for cancer treatment (including, but not limited to, sipuleucel-T …